National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Avelumab (Bavencio®) in combination with axitinib (Inlyta®) for first line treatment of metastatic renal cell carcinoma. HTA ID: 19046

Avelumab in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.

 

NCPE Assessment Process Complete
Rapid review commissioned 29/10/2019
Rapid review completed 02/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avelumab and axitinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 07/01/2020
Pre-submission consultation with Applicant 18/02/2020
Full submission received from Applicant 31/07/2020
Preliminary Review sent to Applicant 02/02/2021
NCPE assessment re-commenced 09/03/2021
Preliminary Review follow up questions sent to Applicant 24/03/2021
NCPE assessment re-commenced 14/04/2021
Factual accuracy check sent to Applicant 28/05/2021
NCPE assessment re-commenced 04/06/2021
NCPE assessment completed 23/06/2021
NCPE assessment outcome The NCPE recommends that avelumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

 

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013